In these trials, the disruption of the erythroid enhancer of BCL11A using the CRISPR-Cas9 system resulted in sustained normal Hb levels 12.5±1.8 g/dl for SCD and 13.1±1.4 g/dl for beta- thalassemia patients After the gene therapy, the 91% of the thalassemic patients were transfusion independent and the 97% of the SCD had reduced vaso-occlusive crisis for a period of 12 months or more [217,218,219]. This evidence concerns the gene GSTM1 and Schnyder corneal dystrophy.